| Literature DB >> 21595917 |
Liviana Da Dalt1, Chiara Chillemi, Maria Elena Cavicchiolo, Silvia Bressan, Arianna Calistri, Giorgio Palù, Giorgio Perilongo.
Abstract
BACKGROUND: Data on clinical presentation, morbidity and mortality of 2009 pandemic influenza virus (H1N1v) in paediatric population are still emerging; most of the data so far available came from selected cohorts of children admitted to tertiary care paediatric hospitals.Entities:
Mesh:
Year: 2011 PMID: 21595917 PMCID: PMC3125342 DOI: 10.1186/1824-7288-37-24
Source DB: PubMed Journal: Ital J Pediatr ISSN: 1720-8424 Impact factor: 2.638
Figure 1Epidemiologic curve of hospitalization H1N1v virus infection (October 2009 and January 2010).
Demographic features and pre-existing conditions of the study population.
| Demographic characteristics | |
|---|---|
| Median | 4.15 |
| Range | 0.8-7.5 |
| <2 | 73 (37) |
| 2-5 | 42 (21) |
| 5-18 | 85 (42) |
| 114 (57) | |
| Caucasian | 156 (78) |
| African | 29 (14.5) |
| Asian | 8 (4) |
| Others | 7 (3.5) |
| 79/200 (40) | |
| Chronic lung disease | 11/79 (14) |
| Asthma | 10/79 (13) |
| Hemoglobinopathy | 11/79 (14) |
| Heart disease | 7/79 (9) |
| Neurological disease | 22/79 (28) |
| Cancer | 5/79 (6) |
| Immunosuppression | 5/79 (6) |
| Other | 8/79 (10) |
| H1N1 vaccine, N° (%) | 3 (2) |
| Seasonal influenza vaccine, N° (%) | 7 (4) |
Clinical, laboratory and instrumental findings of the study population.
| Fever | 185 (93) |
| Cough | 129 (65) |
| Dyspnoea | 60 (30) |
| Wheezing | 31 (15.5) |
| Chest pain | 6 (3) |
| Rhinorrhea | 69 (35) |
| Asthenia | 98 (49) |
| Myalgia | 7 (4) |
| Abdominal pain | 11 (5) |
| Vomiting | 35 (17.5) |
| Diarrhoea | 10 (5) |
| Rash | 3 (2) |
| Headache | 2 (1) |
| Hypoxemia (sat 02 <93%), N° (%) | 34 (17) |
| Leukocyte count (mm3) - median (range) | 8480 (5447-11987) |
| Neutrophils (%) - median (range) | 64 (39-77) |
| Haemoglobin (g/dl) - median (range) | 11.9 (10.8-13.1) |
| Haemoglobin < 10 g/dL, N° (%) | 28 (14.4) |
| Platelet count per mm3 - median (range) | 268.000 (201.500-355.000) |
| PCR (mg/l) - median (range) | 8.1 (2.3-26.8) |
| Procalcitonin (μg/L) - median (range) | |
| Positive blood culture*- patients N° | 4 |
| Elevated aspartate aminotransferease, N° | 7 |
| Pneumonia - N°/total N° (%) | 107/132 (81.1) |
| Interstitial pneumonia, N° (%) | 25 (24) |
| Lobar consolidation | 79 (73.8) |
| Unilateral consolidation, N° (%) | 44 (41.1) |
| Bilateral consolidation, N° (%) | 20 (18.6) |
| Pleural effusion, N° (%) | 5 (4) |
*S. aureus, Candida glabrata, S. agalactiae, N. meningitidis
Comparison between clinical characteristics of children admitted to the Intensive Care Unit and to the regular ward.
| Variable | Admitted to ICU (11 pts) | Admitted to regular ward (189 pts) | P |
|---|---|---|---|
| 3.8 (2.4-4.6) | 4.3 (0.7-7.6) | 0.834 | |
| 7/4 | 107/82 | 0.885 | |
| 10 (90.9) | 69 (36.5) | 0.0011 | |
| Asthma | 0/11 | 10/189 | 0.94 |
| Other chronic lung disease | 0/11 | 11/189 | 0.88 |
| Hemoglobinopathy | 1/11 | 10/189 | 0.88 |
| Heart disease | 2/11 | 5/189 | 0.06 |
| Neurologic disease | 5/11 | 17/189 | 0.0011 |
| Cancer | 0/11 | 5/189 | 0.65 |
| Immunosuppression | 0/11 | 5/189 | 0.65 |
| Other | 2/11 | 6/189 | 0.09 |
| Fever | 10 (91) | 175 (92.6) | 0.702 |
| Cough | 7 (63.6) | 122 (64.5) | 0.793 |
| Dispnea | 8 (72.7) | 52 (27.5) | 0.0045 |
| Wheezing | 5 (45.5) | 26 (13.7) | 0.0166 |
| Hypoxemia at admission (Sat O2 <93%) | 8 (72.7) | 26 (13.7) | <0.0001 |
| Chest pain | 0 | 6 (3.2) | 0.757 |
| Rhinorrea | 4 (36.4%) | 65 (34.4) | 0.847 |
| Asthenia | 6 (54.5%) | 92 (48.6) | 0.946 |
| Myalgia | 0 | 7 (3.7) | 0.846 |
| Abdominal Pain | 0 | 11 (5.8) | 0.886 |
| Vomiting | 3 (27.3%) | 32 (17) | 0.638 |
| Diarrhea | 0 | 10 (5.3) | 0.940 |
| Leukocyte--per mmc | 5700 (4700-8380) | 8600 (5590-12075) | 0.1186 |
| Neutrophils--per mmc | 73 (47-77) | 64 (39-77) | 0.607 |
| CRP--mg/L | 28.5 (3-64) | 7 (2.2-25.7) | 0.137 |
| Hb--g/dL | 9.8 (8.4-11.1) | 12 (11-13.2) | 0.001 |
| 5/11 (45) | 23/189 (12) | 0.0046 | |
| Abnormal Chest X-rays, N° (%) | 11/11 (100) | 96/121 (79.3) | 0.203 |
| Interstitial/focal consolidation, N° | 2/9 | 23/70 | 0.9143 |
| Unilateral/Bilateral consolidation, N° | 4/5 | 55/15 | 0.0752 |
| Pleural effusion, N° (%) | 1/11(9) | 4/121 (3.3) | NS |
| Antiviral treatment, N° (%) | 9 (81) | 94 (50) | 0.078 |
| Days from onset of symptoms to initiation | 5 (2-6.75) | 3 (1.75-5) | 0.203 |